Author:
Nagore G.,Moreno-Olmedo E.,Suárez-Gironzini V.,Aakki L.,LI Ramos-Garcia,Gómez E.,Garcia A.,Beltran L.,Gomez-Iturriaga A.
Subject
Radiology, Nuclear Medicine and imaging,Oncology,Hematology
Reference17 articles.
1. Which alpha/beta ratio for prostate cancer in 2019?;Cosset;Cancer radiother j soc francaise radiother oncol,2019
2. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy;Martinez;Int J Radiat Oncol Biol Phys,2011
3. Behmueller M, Tselis N, Zamboglou N, Zoga E, Baltas D, Rödel C, et al. High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up. Front Oncol. 2021;11:770959.
4. High dose rate brachytherapy as monotherapy for localised prostate cancer: Review of the current status;Tselis;Clin Oncol,2017
5. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy;Morton;Radiother Oncol J Eur Soc Ther Radiol Oncol,2020
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献